Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Marine carbohydrates offer valuable new resources for drug development

The ocean contains diverse carbohydrates that could serve as valuable resources for drug development. Algae, marine animals and microorganisms produce polysaccharides and related molecules with structures that are uncommon on land, including distinctive sulfate patterns, sugar linkages and branched architectures.

22 Sep 2026

Researchers identify a rare genetic change linked to neurodevelopmental disorder

Research led by Texas Children's Duncan Neurological Research Institute (Duncan NRI) and Baylor College of Medicine identified a rare genetic change that appears to cause a newly recognized neurodevelopmental disorder.

21 Sep 2026

Researchers create virtual cells to accelerate drug discovery efforts

Mitochondria - tiny structures that convert nutrients into energy - are often depicted as discrete kidney bean-shaped objects.

18 Sep 2026

Nighttime light exposure linked to sleep disruption in people with schizophrenia

Sleep problems are common in people with schizophrenia and can worsen quality of life, psychiatric symptoms, cognition, and daily functioning.

18 Sep 2026

Big Picture Bio founded to identify, design and optimize promising cancer combination therapies

Big Picture Bio Ltd., has been founded to identify, design and optimize promising cancer combination therapies, using a generative world model to understand how tumors, immune cells and surrounding tissue interact across disease sites and patient subgroups.

From Big Picture Bio 18 Sep 2026

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

Researchers combined toxin sequence mining with machine learning and deep-learning prediction tools to identify and experimentally test 14 antimicrobial peptide candidates derived from cobra cardiotoxins. Most candidates showed limited antibacterial potency, while CTX-p5 displayed moderate membrane-disrupting activity, revealing both the potential and current limitations of computationally guided venom peptide discovery.

17 Sep 2026

How BioAI is taking hold in the North: A conversation with Geoff Davison

The BioAI Summit catalyzes AI integration in life sciences, focusing on practical outcomes and commercial opportunities for enhanced healthcare innovation.

17 Sep 2026

Simple fecal test could help detect colorectal and pancreatic cancers

Gastrointestinal and pancreatobiliary cancers can be difficult to detect early, creating a need for practical, noninvasive approaches for early detection and risk assessment.

16 Sep 2026

MGI launches VisiOmics in Europe and unveils AI-enabled pathology portfolio at ECP 2026

MGI Tech Co., Ltd. (MGI), a company committed to developing core tools and technologies that drive innovation in life science, today announced the European launch of VisiOmics (PMIF-20RS), a fully automated multiplex immunofluorescence (mIF) staining and imaging system, at the 38th European Congress of Pathology (ECP 2026), held in Stockholm from 12 to 16 September 2026.

From MGI 16 Sep 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, today announced Longevity Vaccines, a research initiative developing treatments that direct a patient's own immune cells to eliminate the earliest cellular drivers of age-related disease.

15 Sep 2026

Malvern Panalytical launches Zetasizer Core – an industry first in biologics plate-based stability screening

Malvern Panalytical's Zetasizer Core integrates DLS, SLS, and DSF in one platform, streamlining biologics discovery with unmatched efficiency and precision.

From Malvern Panalytical 15 Sep 2026

Review highlights solute carriers as targets for central nervous system disorders

Solute carriers (SLCs) are specialized transport proteins that control the movement of nutrients, ions and neurotransmitters across cell membranes and are essential for brain metabolism and neuronal communication.

10 Sep 2026

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

10 Sep 2026

Fourier 80 Duo - Expanding access to NMR

Discover how the Fourier 80 Duo expands access to NMR with powerful benchtop performance, streamlined workflows, and expert insights from Bruker.

From Bruker BioSpin Group 9 Sep 2026

OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive approach to uncover new drug targets, today announced it has been awarded funding through Innovate UK's Investor Partnership Grant, jointly provided by Innovate UK and Empirical Ventures.

From OutSee 9 Sep 2026

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Discover how LumiPore improves intracellular delivery with gentle, high-efficiency transfection for drug discovery and cell therapy research.

From Trince 8 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

LSD deconstruction reveals promising new drug candidates

University of California, Davis researchers have stripped down LSD to the base features responsible for its hallucinogenic and therapeutic effects.

7 Sep 2026

Experimental cancer drug could protect against osteoporosis and weight gain

An experimental cancer drug could stop osteoporosis and help women stay slim after the menopause – according to new research from the University of East Anglia.

7 Sep 2026

AI-designed drug candidate reverses biological age in clinical study

Insilico Medicine ("Insilico"), a clinical-stage company focused on generative AI-driven drug discovery and development, today announced the publication of a new study conducted in collaboration with an international team of scientists from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University and Westlake University.

7 Sep 2026

Drug Discovery News and Research

Further Reading

Marine carbohydrates offer valuable new resources for drug development

Researchers identify a rare genetic change linked to neurodevelopmental disorder

Researchers create virtual cells to accelerate drug discovery efforts

Nighttime light exposure linked to sleep disruption in people with schizophrenia

Big Picture Bio founded to identify, design and optimize promising cancer combination therapies

Researchers mine cobra toxins to uncover a membrane-disrupting antimicrobial peptide

How BioAI is taking hold in the North: A conversation with Geoff Davison

Simple fecal test could help detect colorectal and pancreatic cancers

MGI launches VisiOmics in Europe and unveils AI-enabled pathology portfolio at ECP 2026

Insilico Medicine launches AI initiative to develop longevity vaccines

Malvern Panalytical launches Zetasizer Core – an industry first in biologics plate-based stability screening

Review highlights solute carriers as targets for central nervous system disorders

Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis

Fourier 80 Duo - Expanding access to NMR

OutSee awarded Innovate UK grant for agentic AI pilot study to enhance drug target validation

Advancing intracellular delivery with LumiPore®: A new approach to cell transfection and drug discovery

Could scorpion venom inspire new treatments for liver disease?

LSD deconstruction reveals promising new drug candidates

Experimental cancer drug could protect against osteoporosis and weight gain

AI-designed drug candidate reverses biological age in clinical study

Pharmaron’s drug conjugates platform from idea to XDC eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®